Aktis Oncology logo

Aktis Oncology

Challenger

Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.

Best for: Radiopharmaceuticals
53
AI Score
Grade C
AI Visibility Score (Beta)
HealthcareRadiopharmaceuticalsWebsiteUpdated November 2026

Brand Intelligence Graph

Integrates with
Capabilities
Radiopharmaceuticals

Company Overview

About Aktis Oncology

Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.

Business Model & Competitive Advantage

The company's lead candidate, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, the same protein that Pfizer's bladder cancer drug Padcev binds to. Aktis's approach uses alpha-emitting isotopes which can hit tumor targets outside the scope of other radiopharmaceuticals. A second candidate, Ac-AKY-2519, targets B7-H3 expressing tumors with an IND filing planned for 2026.

Competitive Landscape 2025–2026

Aktis's IPO ranks as the sector's third-largest since the start of 2024, trailing only offerings from Kyverna Therapeutics and CG Oncology, and its successful debut signals renewed public market interest in companies with differentiated platforms and clear clinical milestones in precision oncology.

Curated content • Fact-checked and verified

Key Differentiators

Strong Challenger

Aktis Oncology is an established challenger with significant market presence and competitive offerings in Healthcare & Life Sciences.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

53
→ Stable

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Pfizer logo

Pfizer

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan

Moderna logo

Moderna

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép

Amgen logo

Amgen

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic

Zocdoc logo

Zocdoc

HealthTech
AnalyticsB2bB2cHealthtechMarketplaceMobile FirstPlatformSaas

Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Doximity logo

Doximity

HealthTech
HealthtechSaasB2bB2cStartupPlatformAi PoweredMobile First

Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic

Compare Aktis Oncology with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Aktis Oncology

Claim This Profile

Are you from Aktis Oncology? Verify your company email to claim this profile and keep its description, products, and FAQs up to date.

Claim Aktis Oncology Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Aktis Oncology vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →